"Sulfonamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of compounds that contain the structure SO2NH2.
| Descriptor ID |
D013449
|
| MeSH Number(s) |
D02.065.884 D02.886.590.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sulfonamides".
Below are MeSH descriptors whose meaning is more specific than "Sulfonamides".
This graph shows the total number of publications written about "Sulfonamides" by people in this website by year, and whether "Sulfonamides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 1997 | 1 | 1 | 2 |
| 2000 | 4 | 2 | 6 |
| 2001 | 1 | 1 | 2 |
| 2002 | 4 | 0 | 4 |
| 2003 | 7 | 3 | 10 |
| 2004 | 2 | 2 | 4 |
| 2005 | 2 | 5 | 7 |
| 2006 | 4 | 6 | 10 |
| 2007 | 8 | 2 | 10 |
| 2008 | 8 | 3 | 11 |
| 2009 | 3 | 4 | 7 |
| 2010 | 3 | 3 | 6 |
| 2011 | 6 | 7 | 13 |
| 2012 | 9 | 2 | 11 |
| 2013 | 9 | 3 | 12 |
| 2014 | 10 | 7 | 17 |
| 2015 | 1 | 6 | 7 |
| 2016 | 5 | 4 | 9 |
| 2017 | 4 | 1 | 5 |
| 2018 | 3 | 2 | 5 |
| 2019 | 8 | 2 | 10 |
| 2020 | 5 | 4 | 9 |
| 2021 | 5 | 6 | 11 |
| 2022 | 0 | 5 | 5 |
| 2023 | 1 | 1 | 2 |
| 2024 | 7 | 4 | 11 |
| 2025 | 3 | 6 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sulfonamides" by people in Profiles.
-
Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model. Leukemia. 2025 Nov; 39(11):2697-2707.
-
Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia. Nat Rev Clin Oncol. 2025 Nov; 22(11):847-868.
-
Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth. Mol Cancer Ther. 2025 Aug 01; 24(8):1252-1264.
-
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study. Blood. 2025 Jul 31; 146(5):590-600.
-
Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Haematologica. 2026 Jan 01; 111(1):158-167.
-
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML. J Clin Oncol. 2025 Aug 10; 43(23):2606-2615.
-
Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis. Blood Cancer J. 2025 Apr 15; 15(1):65.
-
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study. Blood Cancer J. 2025 Mar 31; 15(1):50.
-
Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes. Blood. 2025 Mar 13; 145(11):1126-1135.
-
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax?+?Hypomethylating Agent. Am J Hematol. 2025 Feb; 100(2):260-271.